
Invyncible Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 5.8/10
Best for: corporate-parent-disclosed Florida GLP-1 platform with LegitScript seal
Invyncible scores below our bar on medical oversight. Read the score breakdown before signing up.
Semaglutide
Tirzepatide
Price checked on Invyncible’s site,
What the monthly price covers
Medication
Not stated
Provider visits
Not stated
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Invyncible is a Florida-based telehealth platform offering compounded semaglutide and tirzepatide programs for weight management. It openly discloses its corporate parent and physical address and displays a LegitScript certification seal. Prices are posted: its lowest-priced programs blend semaglutide or tirzepatide with vitamins B3 and B5 at $99 and $119, and the standard programs are $119 and $149. Each program is a vial lasting about 4 to 5 weeks, and higher doses can cost more. There's no long-term commitment.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Vetted alternatives to Invyncible
Ro
Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Editorial score · methodology
Collective
Best for: the lowest flat medication price if you can absorb an annual membership fee
Editorial score · methodology
CoreAge Rx
Best for: lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Editorial score · methodology
Invyncible at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $99/mo (see plan details)
- Availability
- 40 states
- FDA status
- No FDA warning letter on record
How we scored Invyncible
Each dimension is scored algorithmically from Invyncible’s published pricing, drugs offered, verification status, and disclosed inclusions, using the same six-dimension framework we apply to every provider.
Value25%
6.9/10At $99/mo (see plan details), Invyncible runs about 45% below the $179 median for GLP-1 providers (each program's lowest listed ongoing monthly price for compounded semaglutide).
Effectiveness25%
6.2/10Invyncible offers both semaglutide and tirzepatide, the two GLP-1 molecules with the strongest published weight-loss trial outcomes. An oral/needle-free option is offered for patients who avoid injections.
User Experience15%
5.2/10Online intake and platform experience; 6 platform features disclosed.
Trust & Safety15%
5.0/10Core details confirmed by our editors; no FDA warning letters on file.
Accessibility10%
6.0/10Invyncible is available in 40 states.
Support10%
3.9/10Invyncible provides standard clinician follow-up; no extended coaching or community program is disclosed.
Each checked against the provider’s own site.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this Invyncible review
Last checked November 2026- Confirmed current pricing across 6 dose/plan tiers
- Confirmed availability in 40 states
- Checked the FDA warning-letter database for enforcement actions
- Walked the provider's public sign-up flow, stopping before payment
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records. See the sources below. Editorial confidence in this data: medium.
What we checked
- Provider's own pricing page
- $99–$229/mo across 6 dose/plan tiers (checked November 2026)
- State pharmacy licensing & LegitScript status
- LegitScript Verified
- FDA warning-letter register
- No letter on file for this provider
What to expect when you sign up with Invyncible
We walked Invyncible’s public signup flow in July 2026 to document the process (the steps, pricing transparency, and what’s required) before you commit. (We don’t create accounts, enter medical information, or check out; this is the observable funnel, not a prescribing outcome.)
- 1Select the area you want help with and begin your evaluation.
- 2A licensed provider reviews your health history and symptoms.
- 3If prescribed, your treatment is shipped directly to your door.
- Offers compounded semaglutide and tirzepatide programs among other treatments, each labeled as compounded and not FDA-approved.
- Prices are posted on the treatments page: from $99 for the semaglutide B3/B5 blend and $119 for the tirzepatide blend, or $119 and $149 for the standard programs, each a vial lasting about 4 to 5 weeks.
- A Shipping/Delivery Information link exists but details are not shown on the homepage.
- No refund or cancellation policy is shown on the public pages.
- Support available by phone, chat, and email Mon-Fri 9am-5pm EST; company based in St. Petersburg, FL.
Invyncible customer support
- Phone
- 855-862-9510
- Hours
- Monday–Friday, 9am–5pm EST
GLP-1 medications Invyncible offers
Tap any medication to read our plain-English guide: how it works, dosing, side effects, and what the trials found.
Peptides Invyncible offers
Beyond GLP-1s, Invyncible also offers these peptides. Tap any for our evidence-based guide.
Pricing
Prices re-verified
Compounded semaglutide with vitamins B3 and B5, listed against $350 and billed as its most affordable semaglutide option. The site says it suits patients already on this formula or whose provider finds a medical need for it. Not available in California or Oregon.
Compounded semaglutide with glycine and vitamin B12, listed against $350.
Standard formula, listed against $275. A program is one vial, not a calendar month; larger-dose programs can cost more. Not available in Alabama, Arkansas, California, Hawaii, Kansas, Massachusetts, Michigan, Mississippi or Oregon.
Compounded oral semaglutide capsules with vitamin B12, listed against $365.
Compounded tirzepatide with vitamins B3 and B5, listed against $325 and billed as its most affordable tirzepatide option. Not available in California or Oregon.
Standard formula, listed against $300. Each program is a 4-week vial; larger-dose programs can cost more. Not available in Alabama, Arkansas, California, Hawaii, Kansas, Massachusetts, Michigan, Minnesota or Oregon.
Ready to get started?
Plans and promotions change often, so check Invyncible's current pricing and active discounts before you decide.
What we like
- Corporate parent disclosed (Nationwide Telemedicine, LLC), unlike most competitors that hide behind trade names
- Physical corporate address published (St. Petersburg, FL)
- LegitScript certification seal displayed
- No long-term commitment required
- Offers both semaglutide and tirzepatide programs
Watch-outs
- A program is a vial lasting about 4 to 5 weeks, and the price can rise as your dose goes up
- Not available in several states, and the excluded list varies by product
- 503A vs 503B designation not specified
- Pharmacy partner not named
- No named medical director or clinical leadership
Invyncible in one line: open about who runs it and what it charges, thin on clinical detail
Invyncible is a Florida telehealth platform that sells semaglutide and tirzepatide programs for weight management, marketed as "Medical Wellness and Weight Management — from home." Its distinguishing trait is something most of its competitors actively avoid: it tells you exactly who is behind the brand. The footer names a real corporate parent, Nationwide Telemedicine, LLC, and publishes a physical address in St. Petersburg, FL. That sounds basic, but a large share of GLP-1 startups hide behind a trade name with no traceable company or location anywhere on the site. If knowing who you're handing your credit card and medical history to matters to you, Invyncible clears a bar a lot of flashier brands don't.
Its weak spot is clinical detail. Invyncible now posts a full price menu and labels its GLP-1s as compounded, but it still does not name the pharmacy that fills your prescription or the clinicians who review your intake.
How pricing works
Invyncible lists every program with a sale price next to a higher list price. Its lowest prices are compounded semaglutide with vitamins B3 and B5 at $99 (listed against $350) and compounded tirzepatide with B3 and B5 at $119 (listed against $325). The site calls these its most affordable options and says they suit patients already on that formula or whose provider finds a medical need for it; they are not sold in California or Oregon. The standard semaglutide program starts at $119 (listed against $275) and the standard tirzepatide program at $149 (listed against $300). A semaglutide blend with glycine and B12 is $145, and semaglutide B12 capsules are $229. There is no long-term commitment.
Read the cadence carefully. A program is a vial, not a calendar month. Invyncible's own example says the starter semaglutide vial lasts about five weeks at a low weekly dose, and higher-dose programs use larger vials that last about four weeks. Its FAQ says the cost can rise as your dose goes up, depending on the program and pharmacy. So the starting price is the entry point, not a flat monthly rate.
What to check before you pay
- Which vial size (program) your provider prescribes, and what the next program up costs
- How long that vial should last at your dose
- Whether your state is excluded: each product page lists states it does not ship to, and the list varies by product
- The cancellation and refund terms, which are not laid out on the public pages
The medications
Invyncible's semaglutide and tirzepatide programs are compounded injections, and the product pages say plainly that compounded versions are not FDA-approved. Several blends add vitamin B12, B3/B5 or glycine. Tirzepatide by mouth is on the menu at Try Ageless, which sells both drugs as dissolving tablets as well as injections. Invyncible says it provides telemedicine consultations and coordinates with licensed pharmacies, but it does not compound or dispense medication itself, and it does not name the pharmacy or say whether it is a 503A or 503B facility. Tablet Health names its four partner compounders, though its terms say no refunds. Its FAQ says you can choose the pharmacy your prescription goes to or ask for a copy of the prescription.
Where Invyncible differs from its peers
The medication menu is standard. Invyncible's difference is corporate transparency: it publishes an explicit LLC parent (Nationwide Telemedicine, LLC), a real street address, and a LegitScript seal in its footer. LegitScript is the accreditation pharmacies and ad platforms lean on to flag legitimate operators, and displaying the seal is a positive signal (though the seal on the page doesn't show a specific ID number). Stack those three things together and you get a provider that's easier to trace and vet as a business than most of its peers.
That transparency has limits. It tells you the company is real and accountable. It does not tell you who the clinicians are: the site refers to licensed providers but names no medical director or clinical leadership, and the refund specifics are not published. So the trust signals are real at the corporate level and thin at the clinical level.
Who should choose it, and who should skip it
Consider Invyncible if traceability and a low entry price matter to you: you want a provider whose parent company and address you can look up, plus a LegitScript seal and posted prices. The no-commitment structure makes a test run lower-risk than a contract-based program.
Skip it if you want a flat monthly price that stays the same as your dose rises, or if you live in one of the excluded states. Skip it too if a named medical director and a published pharmacy partner are non-negotiable for you. You can see how we weigh these trade-offs in our scoring methodology.
Trust and oversight: real at the corporate level, thin at the clinical level
Invyncible is a mixed picture. The reasons to feel good are concrete: a disclosed corporate entity, a real physical address, a LegitScript seal, posted prices, a clear note that its compounded drugs are not FDA-approved, and no long-term lock-in. The reasons to stay cautious are equally concrete: no named pharmacy, no 503A-versus-503B designation, no named clinical leadership, and prices that can climb with your dose. To Invyncible's credit, it has no FDA warning letter on file.
Bottom line
Invyncible is one of the more open GLP-1 brands about who it is and what it charges to start. If you weight corporate accountability heavily and want a low entry price, it's a reasonable provider to vet, as long as you confirm the vial size, what higher doses cost, and the pharmacy in writing before you pay.
The Bottom Line
Invyncible scores below our bar on medical oversight. Read the score breakdown before signing up.
Ready to start with Invyncible?
From $99/mo (see plan details). See current pricing and start your free consultation.
Invyncible might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
- If you want brand-name Ozempic, Wegovy, Mounjaro or Zepbound, consider altRX.
- If you want built-in coaching and behavior-change support, consider Ro.
- If you live outside its coverage area and need nationwide access, consider CoreAge Rx.
Head-to-head
Compare Invyncible vs…
Invyncible scores5.8/10
Side-by-side pricing, medications and scores. Pick a matchup.
Invyncible vs Amazon One Medical
Amazon One Medical scores 8.5/10

Invyncible vs Vytora Health
Vytora Health scores 8.4/10
Scores are our independent editorial ratings out of 10.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this Invyncible review:
Sources & methodology (as of November 2026)
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Invyncible's current pricing
Plans from $99/mo (see plan details). Start your free consultation to check eligibility and today's price.